WNT-β-catenin signaling pathway and its relationship with cancer;La vía de señalizacion Wnt-β-catenina y su relación con cancer

Cirugia y Cirujanos

Volumn 80, Issue 4, 2012, Pages 389-398

  Ochoa Hernández, Alejandra Berenice ^a   Juárez Vázquez, Clara Ibet ^b   Rosales Reynoso, Mónica Alejandra ^b   Barros Núñez, Patricio ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

catenin; Cancer; Diagnosis; Prognosis; Wnt

Indexed keywords

BETA CATENIN; CTNNB1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR PROTEIN; WNT PROTEIN;

ARTICLE; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENE THERAPY; GENETICS; HUMAN; LEUKEMIA; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; WNT SIGNALING PATHWAY;

BETA CATENIN; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENETIC THERAPY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84867546725     PISSN: 00097411     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Desen G, Tenstad E, Nygren MK, Stubberud H, Funderud S, Rian E. Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. BMC Immmunology 2006;7:13.
2. Adamson C, Dennis C, Delaney S, Christiansen J, Monkley S, Kozak C, et al. Isolation and Genetic Mapping of Two Novel Members of the Murine WntGene Family, Wntl 1 and Wntl2, and the Mapping of Wnt5ay Wnt7a. Genomics 1994;24(1):9-13.
3. Nusse R, Varmus HE. Wnt Genes. Cell 1992;69:1073-1087.
4. Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, et al. Wnt/p-Catenin Signaling Pathway as Novel Cancer Drug Targets. Curr Cancer Drug Tar 2004;4(8):653-671.
5. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011;8:97-106.
6. Mlodzik M. Planar cell polarization: do the same mechanisms regu-late drosophila tissue polarity and vertebrate gastrulation? Trends Genet 2002;18:564-571.
7. Miller J. The Wnts. Genome Biology 2001;3:3001.1-3001.15.
8. Bui TD, Lako M, Lejeune S, Curtis AR, Strachan T, Lindsay S, et al. Isolation of a full-length human WNT7A gene implicated in limb development and cell transformation, and mapping to chromosome 3p25. Gene 1997;189(l):25-29.
9. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Signal-ing Pathways That Depend on Regulated Proteolysis. En: Molecular Biology of the Cell. (Eds) Garland Science 4th. Edicion. New York: Garland Science, 2005 p. 893-899.
10. Takahashi-Yanaga F, Sasaguri T. The Wnt/p-Catenin Signaling Path-way as a Target in Drug Discovery. J Pharmacol Sci 2007;104(4):293- 302.
11. Hendrickx M, Leyns L. Non-conventional Frizzled ligands and Wnt receptors. Dev Growth Differ 2008;50(4):229-243.
12. Winn RA, Scoyk MV, Hammond M, Rodriguez K, Crossno JT, Hea-sley LE, et al. Antitumorigenic Effect of Wnt 7a and Fzd 9 in Non- small Cell Lung Cancer Cells Is Mediated through ERK-5-dependent Activation of Peroxisome Proliferator-activated Receptor y. J Biol Chem 2006;281:26943-26950.
13. Kuhl M, Sheldahl LC, Park M, Miller JR, Moon RT. The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet 2000;16(7):279-283.
14. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-850.
15. Willert K, Jones KA. Wnt signaling: is the party in the nucleus? Genes Dev 2006;20:1394-1404.
16. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-1851.
17. Kyoto Encyclopedia of Genes and Genomes. KEGG PATHWAY Da-tabase. 2006. URL http://www.genome.jp/kegg/) 18.
18. Chen AE, Ginty DD, Fan CM. Protein kinase A signalling via CREB con-trols myogenesis induced by Wnt proteins. Nature 2005;433:317- 322.
19. Johnson ML, Rajamannan N. Diseases of Wnt signaling. Rev Endocr Metab Disord 2006;7(l-2):41-49.
20. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810.
21. Luo J, Chen J, Deng ZL, Luo X, Song WX, Sharff KA, et al. Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest 2007;87:97-103.
22. Clement G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J. Alterations of the Wnt signaling pathway during the neoplastic pro-gression ofBarrett's esophagus. Oncogene 2006;25:3084-3092.
23. Vermeulen L, De Sousa E Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010;12:468-476.
24. Korkaya H, Wicha MS. Cancer stem cells: nature versus nurture. Nat Cell Biol 2010;12:419-421.
25. Villanueva T. Cancer stem cells: Wnt-looking outside in. Nat Rev Cancer 2010;10:386-387.
26. Kirikoshi H, Katoh M. Expression of WNT7A in human normal tis-sues and cancer, and regulation of WNT7A and WNT7B in human cancer. Int J Oncol 2002;21(4):895-900.
27. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, et al. Ac-tivation of the Wnt signaling pathway in chronic lymphocytic leuke-mia. PNAS 2004;101(9):3118-3123.
28. Jonsson M, Dejmek J, Bendahl PO, Andersson T. Loss of Wnt-5a Protein Is Associated with Early Relapse in Invasive Ductal Breast Carcinomas. Cancer Res 2002;62:409-416.
29. Liang H, Chen Q, Coles AH, Anderson SJ, Pihan G, Bradley A, et al. Wnt5a inhibits B cell proliferation and functions as a tumor suppres-sor in hematopoietic tissue. Cancer Cell 2003;4(5):349-360.
30. Ying Y, Tao Q. Epigenetic disruption of the WNT/p-catenin signaling pathway in human cancers. Epigenetics 2009;4(5):307-312.
31. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and p-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5:691-701.
32. Clevers H. Wnt/p Catenin Signaling in Development and Disease. Cell 2006;127(3):469-480.
33. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428.
34. He B, Lee AY, Dadfarmay S, You L, Xu Z, Reguart N, et al. Secreted Frizzled-Related Protein 4 Is Silenced by Hypermethylation and In-duces Apoptosis in p-Catenin-Deficient Human Mesothelioma Cells. Cancer Res 2005;65:743-748.
35. Baylin SB, Ohm JE. Epigenetics gene silencing in cancer - a mech-anism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-116.
36. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417-422.
37. Zhang W, Glockner SC, Guo M, Machida EO, Wang DH, Easwaran H, et al. Epigenetic Inactivation of the Canonical Wnt Antagonist SRY-Box Containing Gene 17 in Colorectal Cancer. Cancer Res 2008;68:2764-2772.
38. Fu DY, Wang ZM, Li-Chen, Wang BL, Shen ZZ, Huang W, et al. Soxl7, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Cancer Res treat 2010;119(3):601-612.
39. Topol L, Jiang X, Choi H, Garret-Beal L, Carolan PJ, Yang Y. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-indepen- dent p-catenin degradation. J Cell Biol 2003;162(5):899-908.
40. Saitoh T, Mine T, Katoh M. Frequent up-regulation of WNT5A mRNAin primary gastric cancer. Int J Mol Med 2002;9(5):515-519.
41. Leris ACA, Roberts TR, Jiang WG, Newbold RF, Mokbel K. WNT5A Expression in Human Breast Cancer. Anticancer Res 2005;25(2A):731-734.
42. Ying J, Li H, Yu J, Ng KM, Poon FF, Wong SCC, et al. WNT5A Ex-hibits Tumor-Suppressive Activity through Antagonizing the Wnt/p- Catenin Signaling, and Is Frequently Methylated in Colorectal Can-cer. Clin Cancer Res 2008;14:55-61.
43. Urakami S, Shiina H, Enokida H. Hirata H, Kawamoto K, Kawakami T, et al. Wnt Antagonist Family Genes as Biomarkers for Diagnosis, Staging, and Prognosis of Renal Cell Carcinoma Using Tumor and Serum DNA. Clin Cancer Res 2006;12:6989-6997.
44. Yu J, Tao Q, Cheng YY, Lee KY, Ng SSM, Cheung KF, et al. Promot-er methylation of the Wnt/p-catenin signaling antagonist Dkk-3 is as-sociated with poor survival in gastric cancer. Cancer 2009;115(1):49- 60.
45. Veeck J, Wild PJ, Fuchs T, Schuffler PJ, Hartmann A, Knuchel R, et al. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dick- kopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer 2009;9:217.
46. Veek J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavorable prognosis. Oncogene 2006;25:3479-3488.
47. Chim CS, Chan WWL, Pang A, Kwong YL. Preferential methyla-tion of Wnt inhibitory factor-1 in acute promyelocyte leukemia: an independent poor prognostic factor. Leukemia 2006;20:907-909.
48. Jiang X, Tan J, Li J, Kivimae S, Yang X, Zhuang L, et al. DACT3 Is an Epigenetic Regulator of Wnt/p-Catenin Signaling in Colorectal Cancer and Is a Therapeutic Target of Histone Modifications. Cancer Cell 2008;13(6):529-541.
49. Cheng JC, Yoo CB, Weisenberg DJ, Chuang J, Wozniak C, Liang G, et al. Preferential response of cancer cells to zebularine. Cancer Cell 2004;6(2):151-158.
50. Curtin JC, Lorenzi MV. Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells. Oncotarget 2010;l(7):552-566.
51. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-107.
52. Takahashi-Yanaga F, Kahn M. Targeting Wnt Signaling: Can We Safe-ly Eradicate Cancer Stem Cells? Clin Cancer Res 2010;16:3153-3162.